Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus
Copyright © 2018 Elsevier Ltd. All rights reserved..
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Vaccine - 36(2018), 24 vom: 07. Juni, Seite 3468-3476 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jung, Seo-Yeon [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.09.2018 Date Revised 19.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2018.04.082 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283866632 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283866632 | ||
| 003 | DE-627 | ||
| 005 | 20231225041906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2018.04.082 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0946.xml |
| 035 | |a (DE-627)NLM283866632 | ||
| 035 | |a (NLM)29739720 | ||
| 035 | |a (PII)S0264-410X(18)30598-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jung, Seo-Yeon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2018 | ||
| 500 | |a Date Revised 19.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two types of MERS-CoV vaccines: a recombinant adenovirus serotype 5 encoding the MERS-CoV spike gene (Ad5/MERS) and spike protein nanoparticles formulated with aluminum (alum) adjuvant. Next, we tested a heterologous prime-boost vaccine strategy, which compared priming with Ad5/MERS and boosting with spike protein nanoparticles and vice versa, with homologous prime-boost vaccination comprising priming and boosting with either spike protein nanoparticles or Ad5/MERS. Although both types of vaccine could induce specific immunoglobulin G against MERS-CoV, neutralizing antibodies against MERS-CoV were induced only by heterologous prime-boost immunization and homologous immunization with spike protein nanoparticles. Interestingly, Th1 cell activation was induced by immunization schedules including Ad5/MERS, but not by those including only spike protein nanoparticles. Heterologous prime-boost vaccination regimens including Ad5/MERS elicited simultaneous Th1 and Th2 responses, but homologous prime-boost regimens did not. Thus, heterologous prime-boost may induce longer-lasting immune responses against MERS-CoV because of an appropriate balance of Th1/Th2 responses. However, both heterologous prime-boost and homologous spike protein nanoparticles vaccinations could provide protection from MERS-CoV challenge in mice. Our results demonstrate that heterologous immunization by priming with Ad5/MERS and boosting with spike protein nanoparticles could be an efficient prophylactic strategy against MERS-CoV infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adenovirus 5 | |
| 650 | 4 | |a Heterologous prime–boost | |
| 650 | 4 | |a MERS-CoV | |
| 650 | 4 | |a Th1 | |
| 650 | 4 | |a Th2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Alum Compounds |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Kang, Kyung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Eun-Young |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Dong-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hong-Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hak |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, TaeWoo |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Hye-Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang-Myeong |e verfasserin |4 aut | |
| 700 | 1 | |a Nam, Jae-Hwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 36(2018), 24 vom: 07. Juni, Seite 3468-3476 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2018 |g number:24 |g day:07 |g month:06 |g pages:3468-3476 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2018.04.082 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2018 |e 24 |b 07 |c 06 |h 3468-3476 | ||